

Adult CIRB - Early Phase Emphasis Meeting Agenda

May 2, 2023

I New Study - Initial Review

10556, Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma (Version Date 03/15/23)

II Continuing Review

10302, Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer (Version Date 10/10/22)

III Continuing Review

10401, A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma (Version Date 03/27/23)

IV Continuing Review

10186, A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent Highgrade Radiation-relapsed Meningioma (Version Date 01/09/23)

V Continuing Review

10291, A Phase 1b Study of Berzosertib in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (Version Date 09/16/22)



VI Continuing Review

9892, Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer (Version Date 01/12/23)